IHE Publications

Optimizing care for patients in Canada with severe, persistent mental illness: a focus on pharmacologic therapy: A Roundtable Report

Severe, persistent, mental illness (SPMI) does not refer to a specific mental disorder, but is an umbrella term that describes mental illness associated with significant impairment in activities in daily living, and requiring treatment over a prolonged period of time, typically 2 or more years. In the spring of 2024 the IHE conducted a facilitated, evidence-informed discussion with a broad group of stakeholders focused on the issue of optimizing care for those dealing with severe persistent mental illness (SPMI), with a focus on pharmacological therapies.  

A number of issues represent challenges to optimizing the use of pharmacologic therapies including: how care is organized, how new therapies are evaluated, how patients and payers perceive the need for new therapies differently, the lack of access to therapies available in other markets, the costs of medications and policies that do not address equitable access. A number of actions that could lead to positive outcomes for patients were identified in deliberation and would require leadership from all stakeholders including Federal and Provincial governments (including Health Canada), public and private payers, health technology assessment (HTA) bodies and manufacturers and care coordination programs

The initiative was supported through funding from Abbvie Canada. The views expressed herein do not necessarily represent the official position of AbbVie Canada Inc. or individual participants and organizations who participated in this work.

Publication Type: IHE Roundtable Report

Year of Publication: 2024

Topics: Mental Health, Pharmaceutical Policy

Authors: Don Husereau, John Sproule